FDA Says Finalizing Opioid Guide A Priority, But Doesn't Commit To Congress' Deadline

An FDA official said issuance of a final abuse-deterrent opioid evaluation and labeling guidance is a priority but wouldn't publicly commit to the June 30 deadline set by Congress. Lawmakers included language in the year-end spending package that withholds $20 million in salaries and expenses from the FDA commissioner's office pending finalization of the guidance and warns the funding will be shifted if the document isn't out by the due date. “Although an exact release date cannot be determined at...